Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
9.81
+0.22 (2.29%)
At close: Mar 9, 2026, 4:00 PM EDT
9.81
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:52 PM EDT
Prothena Corporation Revenue
In the year 2025, Prothena Corporation had annual revenue of $9.68M, down -92.84%. Prothena Corporation had revenue of $21.00K in the quarter ending December 31, 2025, a decrease of -99.01%.
Revenue (ttm)
$9.68M
Revenue Growth
-92.84%
P/S Ratio
54.87
Revenue / Employee
$59,411
Employees
163
Market Cap
528.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | -125.47M | -92.84% |
| Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
| Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
| Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
| Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Zevra Therapeutics | 84.39M |
| ADC Therapeutics | 75.21M |
| Invivyd | 53.43M |
| Ocugen | 4.41M |
| Allogene Therapeutics | 22.00K |
PRTA News
- 6 days ago - Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution - Seeking Alpha
- 10 days ago - Prothena Announces up to $100 Million Share Repurchase Plan - Business Wire
- 17 days ago - Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire
- 25 days ago - Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
- 3 months ago - Prothena Announces Board of Directors Update - Business Wire
- 3 months ago - Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - Business Wire
- 4 months ago - Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA - Business Wire